Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

Abstract

Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to Asn297 of the Fc is essential for antibody effector functions, fucose and outer-arm sugars attached to the core heptasaccharide that generate structural heterogeneity (glycoforms) exhibit unique biological activities. Hence, efficient and quantitative glycan analysis techniques have been increasingly important for the development and quality control of therapeutic antibodies, and glycan profiles of the Fc are recognized as critical quality attributes. In the past decade our understanding of the influence of glycosylation on the structure/function of IgG-Fc has grown rapidly through X-ray crystallographic and nuclear magnetic resonance studies, which provides possibilities for the design of novel antibody therapeutics. Furthermore, the chemoenzymatic glycoengineering approach using endoglycosidase-based glycosynthases may facilitate the development of homogeneous IgG glycoforms with desirable functionality as nextgeneration therapeutic antibodies. Thus, the Fc glycans are fertile ground for the improvement of the safety, functionality, and efficacy of therapeutic IgG antibodies in the era of precision medicine.

Key words： chemoenzymatic glycoengineering; crystal structure; endoglycosidase; fucose; glycosylation; intravenous immunoglobulin; sialic acid; transglycosylation; ultra performance liquid chromatography

References

1 Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ (2014) Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol 426:3166–3179

2 Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F (2008) In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci USA 105:15005–15009

3 Allhorn M, Collin M (2009) Sugar-free antibodies—the bacterial solution to autoimmunity? Ann N Y Acad Sci 1173:664–669

4 Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475:110–113

5 Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV (2008a) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373–376

6 Anthony RM, Wermeling F, Karlsson MC, Ravetch JV (2008b) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 105:19571–19578

7 Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA (2006) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21–50

8 Ashwell G, Harford J (1982) Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51:531–554

9 Barb AW, Brady EK, Prestegard JH (2009) Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry 48:9705–9707

10 Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH (2012) NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 51:4618–4626

11 Baruah K, Bowden TA, Krishna BA, Dwek RA, Crispin M, Scanlan CN (2012) Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J Mol Biol 420:1–7

12 Bazin R, Lemieux R, Tremblay T (2006) Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 135:97–100

13 Bones J, Mittermayr S, O’Donoghue N, Guttman A, Rudd PM (2010) Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem 82:10208–10215

14 Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G (2012) Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 7:1596–1602

15 Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colonystimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573–581

16 Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW, Neschadim A, Leontyev D (2014) Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol 192:5031–5038

17 Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D (2008) Cetuximabinduced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 358:1109–1117

18 Collin M, Shannon O, Bjorck L (2008) IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci USA 105:4265–4270

19 Crispin M, Yu X, Bowden TA (2013) Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci USA 110:E3544–3546

20 Davies AM, Jefferis R, Sutton BJ (2014a) Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol 62:46–53

21 Davies AM, Rispens T, Ooijevaar-de Heer P, Gould HJ, Jefferis R, Aalberse RC, Sutton BJ (2014b) Structural determinants of unique properties of human IgG4-Fc. J Mol Biol 426:630–644

22 Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C (1993) Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342:945–949

23 Deisenhofer J (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 20:2361–2370

24 Delord JP, Tabernero J, Garcia-Carbonero R, Cervantes A, Gomez-Roca C, Berge Y, Capdevila J, Paz-Ares L, Roda D, Delmar P(2014) Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. Eur J Cancer 50:496–505

25 Doherty M, McManus CA, Duke R, Rudd PM (2012) High-throughput quantitative N-glycan analysis of glycoproteins. Methods Mol Biol 899:293–313

26 Dwek RA (1998) Biological importance of glycosylation. Dev Biol Stand 96:43–47

27 Fan SQ, Huang W, Wang LX (2012) Remarkable transglycosylation activity of glycosynthase mutants of endo-D, an endo-beta-Nacetylglucosaminidase from Streptococcus pneumoniae. J Biol Chem 287:11272–11281

28 Feige MJ, Nath S, Catharino SR, Weinfurtner D, Steinbacher S, Buchner J (2009) Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol 391:599–608

29 Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M (2011) Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 108:12669–12674

30 Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281:5032–5036

31 Fujita K, Kobayashi K, Iwamatsu A,Takeuchi M, Kumagai H, Yamamoto K (2004) Molecular cloning of Mucor hiemalis endobeta-N-acetylglucosaminidase and some properties of the recombinant enzyme. Arch Biochem Biophys 432:41–49

32 Gala FA, Morrison SL (2004) V region carbohydrate and antibody expression. J Immunol 172:5489–5494

33 Galili U, Anaraki F, Thall A, Hill-Black C, Radic M (1993) One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82:2485–2493

34 Ghirlando R, Keown MB, Mackay GA, Lewis MS, Unkeless JC, Gould HJ (1995) Stoichiometry and thermodynamics of the interaction between the Fc fragment of human IgG1 and its lowaffinity receptor Fc gamma RIII. Biochemistry 34:13320–13327

35 Giddens JP, Wang LX (2015) Chemoenzymatic Glyco-engineering of Monoclonal Antibodies. Methods Mol Biol 1321:375–387

36 Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC (2011) High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21:949–959

37 Grey AA, Narasimhan S, Brisson JR, Schachter H, Carver JP (1982) Structure of the glycopeptides of a human gamma 1-immunoglobulin G (Tem) myeloma protein as determined by 360-megahertz nuclear magnetic resonance spectroscopy. Can J Biochem 60:1123–1131

38 Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, Rispens T (2011) Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulinGin a murine model of immune thrombocytopenia. PloS One 6:e21246

39 Ha S, Wang Y, Rustandi RR (2011) Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris. MAbs 3:453–460

40 Higel F, Seidl A, Sorgel F, Friess W (2016) N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm 100:94–100

41 Holland M, Yagi H, Takahashi N, Kato K, Savage CO, Goodall DM, Jefferis R (2006) Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCAassociated systemic vasculitis. Biochim Biophys Acta 1760:669–677

42 Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX (2012) Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc 134:12308–12318

43 Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M (2006) Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulinGon antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 12:2879–2887

44 Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H(2012) Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30:837–842

45 Iwamoto T, Okamoto A, Ishinaga H, Shimizu K, Gayle AA, Arai N, Takeuchi K, Okuda M (2016) A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drugspecific IgE on basophils. Cancer Med 5:1004–1012

46 Jefferis R (2009) Glycosylation as a strategy to improve antibodybased therapeutics. Nat Rev Drug Discov 8:226–234

47 Jefferis R (2012) Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 526:159–166

48 Jefferis R (2017) Characterization of biosimilar biologics: the link between structure and functions. In: Endrenyi L, Declerck P, Chow S-C (eds) Drugs and the pharmaceutical sciences. CRC Press, Boca Raton, pp 109–149

49 Ju MS, Jung ST (2014) Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. Curr Opin Biotechnol 30:128–139

50 Ju MS, Na JH, Yu YG, Kim JY, Jeong C, Jung ST (2015) Structural consequences of aglycosylated IgG Fc variants evolved for FcgammaRI binding. Mol Immunol 67:350–356

51 Jung ST, Kang TH, Kelton W, Georgiou G (2011) Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol 22:858–867

52 Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G(2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci USA 107:604–609

53 Kanda Y,Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S (2007) Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17:104–118

54 Kaneko Y,Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673

55 Kao D, Danzer H, Collin M, Gross A, Eichler J, Stambuk J,Lauc G, Lux A, Nimmerjahn F (2015) A monosaccharide residue is sufficient to maintain mouse and human IgG subclass activity and directs IgG effector functions to cellular Fc receptors. Cell Rep 13:2376–2385

56 Kato T, Fujita K, Takeuchi M, Kobayashi K, Natsuka S, Ikura K, Kumagai H, Yamamoto K (2002) Identification of an endo-beta-Nacetylglucosaminidase gene in Caenorhabditis elegans and its expression in Escherichia coli. Glycobiology 12:581–587

57 Kobayashi S, Kiyosada T, Shoda S-I (1996) Enzymatic synthesis of chondroitin and its derivatives catalyzed by hyaluronidase. J Am Chem Soc 118:13113–13114

58 Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M (1997) Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90:1109–1114

59 Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325:979–989

60 Kurogochi M, Mori M, Osumi K, Tojino M, Sugawara S, Takashima S, Hirose Y, Tsukimura W, Mizuno M, Amano J (2015) Glycoengineered monoclonal antibodies with homogeneous glycan (M3, G0, G2, and A2) using a chemoenzymatic approach have different affinities for FcgammaRIIIa and Variable antibodydependent cellular cytotoxicity activities. PloS One 10:e0132848

61 Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J,Risteli L, Lee YC, Feizi T, Langen H, Nussenzweig MC (2002) Mannose receptormediated regulation of serum glycoprotein homeostasis. Science 295:1898–1901

62 Leontyev D,Katsman Y, Branch DR (2012a) Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood 119:5261–5264

63 Leontyev D, Katsman Y,Ma XZ, Miescher S, Kasermann F, Branch DR (2012b) Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52:1799–1805

64 Li B, Zeng Y, Hauser S, Song H, Wang LX (2005) Highly efficient endoglycosidase-catalyzed synthesis of glycopeptides using oligosaccharide oxazolines as donor substrates. J Am Chem Soc 127:9692–9693

65 Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi BK, Cook WJ, Cukan M(2006) Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24:210–215

66 Li T,Tong X, Yang Q, Giddens JP, Wang LX (2016) Glycosynthase mutants of endoglycosidase S2 show potent transglycosylation activity and remarkably relaxed substrate specificity for antibody glycosylation remodeling. J Biol Chem 291:16508–16518

67 Lin CW, Tsai MH, Li ST, Tsai TI, Chu KC, Liu YC, Lai MY, Wu CY, Tseng YC, Shivatare SS (2015) A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc Natl Acad Sci USA 112:10611–10616

68 Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104:1866–1884

69 Liu L (2017) Pharmacokinetics of monoclonal antibodies and Fcfusion proteins. Protein Cell.

70 Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, Hochman J, Prueksaritanont T (2011) Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. Biologicals 39:205–210

71 Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R (1990) A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol Immunol 27:1145–1153

72 Maenaka K, van der Merwe PA, Stuart DI, Jones EY, Sondermann P (2001) The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem 276:44898–44904

73 Mariotte D, Dupont B, Gervais R, Galais MP, Laroche D, Tranchant A, Comby E, Bouhier-Leporrier K, Reimund JM, Le Mauff B (2011) Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 3:396–401

74 Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K (2007) Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368:767–779

75 Mimura Y, Ashton PR, Takahashi N, Harvey DJ, Jefferis R (2007) Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J Immunol Methods 326:116–126

76 Mimura Y, Church S, Ghirlando R, Ashton PR,Dong S, Goodall M, Lund J, Jefferis R(2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 37:697–706

77 Mimura Y, Jefferis R, Mimura-Kimura Y, Abrahams J,Rudd PM (2009) Glycosylation of therapeutic IgGs. In: An Z (ed) Therapeutic monoclonal antibodies: from the Bench to the Clinic. Wiley, Hoboken, pp 67–89

78 Mimura Y, Kelly RM, Unwin L, Albrecht S, Jefferis R,Goodall M, Mizukami Y,Mimura-Kimura Y, Matsumoto T, Ueoka H (2016) Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines. J Immunol Methods 428:30–36

79 Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, Jefferis R (2001) Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem 276:45539–45547

80 Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K (2011) Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16:1071–1080

81 Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402

82 Muramatsu H, Tachikui H, Ushida H, Song X, Qiu Y, Yamamoto S, Muramatsu T (2001) Molecular cloning and expression of endobeta-N-acetylglucosaminidase D, which acts on the core structure of complex type asparagine-linked oligosaccharides. J Biochem 129:923–928

83 Niwa R, Natsume A,Uehara A ,Wakitani M, Iida S, Uchida K,Satoh M, Shitara K (2005) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J ImmunolMethods 306:151–160

84 Noguchi M, Fujieda T, Huang WC, Ishihara M, Kobayashi A, Shoda S-I (2012) A practical one-step synthesis of 1,2-oxazoline derivatives from unprotected sugars and its application to chemoenzymatic beta-N-acetylglucosaminidation of disialooligosaccharide. Helv. Chim. Acta 95:1928–1936

85 Noguchi M, Tanaka T, Gyakushi H, Kobayashi A, Shoda S (2009) Efficient synthesis of sugar oxazolines from unprotected N-acetyl-2-amino sugars by using chloroformamidinium reagent in water. J Org Chem 74:2210–2212

86 Nose M, Wigzell H (1983) Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA 80:6632–6636

87 Okazaki A, Shoji-Hosaka E,Nakamura K , Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336:1239–1249

88 Othy S, Topcu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Kasermann F, Miescher S, Bayry J, Kaveri SV (2014) Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur J Immunol 44:2059–2063

89 Padlan EA (1990) X-ray diffraction studies of antibody constant regions. In: Metzger H (ed) Fc receptors and the action of antibodies. American Society for Microbiology, Washington, DC, pp 12–30

90 Pound JD, Lund J, Jefferis R (1993) Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol Immunol 30:233–241

91 Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik O, Supraha-Goreta S, Wormald MR, Redzic I (2011) High throughput isolation and glycosylation analysis of IgGvariability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10(M111):010090

92 Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q (2007) Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrixassisted laser desorption/ionization hybrid quadrupole–quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 364:8–18

93 Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Munz C, Nimmerjahn F, Dalakas MC, Lunemann JD (2015) Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125:4160–4170

94 Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276:16469–16477

95 Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y,Sim RB , Inoges S (2007) Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 282:7405–7415

96 Raju TS, Briggs JB, Borge SM, Jones AJ (2000) Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10:477–486

97 Raymond C, Robotham A, Spearman M, Butler M, Kelly J, Durocher Y (2015) Production of alpha2,6-sialylated IgG1 in CHO cells. MAbs 7:571–583

98 Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725

99 Royle L, Radcliffe CM, Dwek RA, Rudd PM (2006) Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol Biol 347:125–143

100 Rudd PM, Dwek RA (1997) Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 32:1–100

101 Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R (1992) Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor. Mol Immunol 29:633–639

102 Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA 105:20167–20172

103 Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524–1534

104 Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, Frances-Lasserre S, Carlile DJ, Crump M (2012) A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119:5118–5125

105 Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33:3467–3474

106 Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K,Kato K (2009) The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 19:126–134

107 Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fucose on human IgG1N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J BiolChem 277:26733–26740

108 Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591–6604

109 Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J Biol Chem 278:3466–3473

110 Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P (2002) Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 263:133–147

111 Sondermann P, Huber R, Jacob U (1999) Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J 18:1095–1103

112 Sondermann P,Huber R, Oosthuizen V, Jacob U (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406:267–273

113 Sondermann P, Jacob U (1999) Human Fcgamma receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol Chem 380:717–721

114 Sun B, Bao W, Tian X, Li M, Liu H, Dong J, Huang W (2014) A simplified procedure for gram-scale production of sialylglycopeptide (SGP) from egg yolks and subsequent semi-synthesis of Man3GlcNAc oxazoline. Carbohydr Res 396:62–69

115 Takegawa K, Tabuchi M, Yamaguchi S, Kondo A, Kato I, Iwahara S (1995) Synthesis of neoglycoproteins using oligosaccharidetransfer activity with endo-beta-N-acetylglucosaminidase. J Biol Chem 270:3094–3099

116 Takegawa K, Yamabe K, Fujita K, Tabuchi M, Mita M, Izu H, Watanabe A, Asada Y, Sano M, Kondo A (1997) Cloning, sequencing, and expression of Arthrobacter protophormiae endobeta-N-acetylglucosaminidase in Escherichia coli. Arch Biochem Biophys 338:22–28

117 Takeuchi M, Takasaki S, Miyazaki H, Kato T, Hoshi S, Kochibe N, Kobata A (1988) Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 263:3657–3663

118 Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100:12045–12050

119 Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143:2595–2601

120 Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J (2013) Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122:1419–1427

121 Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176–180

122 Umekawa M, Li C, Higashiyama T, Huang W, Ashida H, Yamamoto K, Wang LX (2010) Efficient glycosynthase mutant derived from Mucor hiemalis endo-beta-N-acetylglucosaminidase capable of transferring oligosaccharide from both sugar oxazoline and natural N-glycan. J Biol Chem 285:511–521

123 van den Eijnden DH, Joziasse DH, Dorland L, van Halbeek H, Vliegenthart JF, Schmid K (1980) Specificity in the enzymic transfer of sialic acid to the oligosaccharide branches of b1- and triantennary glycopeptides of alpha 1-acid glycoprotein. Biochem Biophys Res Commun 92:839–845

124 Wang B, Yan L, Yao Z, Roskos LK (2017) Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma. CPT Pharmacomet Syst Pharmacol. 6(4):249–257

125 Wei Y, Li C, Huang W, Li B, Strome S, Wang LX (2008) Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. Biochemistry 47:10294–10304

126 Woof JM, Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4:89–99

127 Wright A, Tao MH, Kabat EA, Morrison SL (1991) Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J 10:2717–2723

128 Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP (1997) A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059–1070

129 Wu SJ, Luo J, O’Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS (2010) Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 23:643–651

130 Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, Kato K (2006) Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta 1760:693–700

131 Yamamoto K, Kadowaki S, Fujisaki M, Kumagai H, Tochikura T (1994) Novel specificities of Mucor hiemalis endo-beta-N-acetylglucosaminidase acting complex asparagine-linked oligosaccharides. Biosci Biotechnol Biochem 58:72–77

132 Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591–1598

133 Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87:614–622

134 Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN (2013) Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 425:1253–1258

135 Zhang P, Woen S, Wang T, Liau B, Zhao S, Chen C, Yang Y, Song Z, Wormald MR, Yu C (2016) Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov Today 21:740–765

136 Zhu A, Hurst (2002) Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9:376–381